Literature DB >> 29313973

Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer.

Maxime Mermod1, Agnès Hiou-Feige1, Esther Bovay2, Vincent Roh1, Jana Sponarova1, Massimo Bongiovanni3, Daniel W Vermeer4, John H Lee4, Tatiana V Petrova2, Jean-Paul Rivals1, Yan Monnier1, Genrich V Tolstonog1, Christian Simon1.   

Abstract

HPV-positive head and neck squamous cell carcinoma (HNSCC) is increasingly frequent. Management is particularly debated in the case of postsurgical high-risk features, that is, positive surgical margins and extracapsular spread (ECS). In this increasingly complex emerging framework of HNSCC treatment, representative preclinical models are needed to support future clinical trials and advances in personalized medicine. Here, we present an immunocompetent mouse model based on the implantation of mouse tonsil epithelial HPV16-E6/E7-expressing cancer cells into the submental region of the floor-of-the-mouth. Primary tumors were found to replicate the patterns of human HNSCC local invasion and lymphatic dissemination. To study disease progression after surgery, tumors were removed likely leaving behind residual disease. Surgical resection of tumors was followed by a high rate of local recurrences (>90%) within the first 2-3 weeks. While only 50% of mice had lymph node metastases (LNM) at time of primary tumor excision, all mice with recurrent tumors showed evidence of LNM. To study the consecutive steps of LNM progression and distant metastasis development, LNs from tumor-bearing mice were transplanted into naïve recipient mice. Using this approach, transplanted LNs were found to recapitulate all stages and relevant histological features of regional metastasis progression, including ECS and metastatic spread to the lungs. Altogether, we have developed an immunocompetent HPV-positive HNSCC mouse model of postsurgical local recurrence and regional and distant metastasis progression suitable for preclinical studies.
© 2018 UICC.

Entities:  

Keywords:  HNSCC; HPV; metastasis; minimal residual disease; mouse model; recurrence; surgery

Mesh:

Year:  2018        PMID: 29313973     DOI: 10.1002/ijc.31240

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin.

Authors:  Samriddhi Shukla; David Milewski; Arun Pradhan; Nihar Rama; Kathryn Rice; Tien Le; Matthew J Flick; Sara Vaz; Xueheng Zhao; Kenneth D Setchell; Elsa Logarinho; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  Mol Cancer Ther       Date:  2019-04-30       Impact factor: 6.261

2.  Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy.

Authors:  Elisabeth G Vichaya; Bianca G Ford; Jessica M Moltenkine; Cullen M Taniguchi; A Phillip West; Robert Dantzer
Journal:  Brain Behav Immun       Date:  2021-08-19       Impact factor: 7.217

3.  Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.

Authors:  Sonia Domingos-Pereira; Vincent Roh; Agnès Hiou-Feige; Gabriele Galliverti; Christian Simon; Genrich V Tolstonog; Denise Nardelli-Haefliger
Journal:  Oncoimmunology       Date:  2021-04-13       Impact factor: 8.110

4.  Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1.

Authors:  Deeptashree Nandi; Pradeep Singh Cheema; Aakriti Singal; Hina Bharti; Alo Nag
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

5.  Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor.

Authors:  Daniela R Montagna; Alejandra Duarte; Paula Chiarella; Bárbara Rearte; Oscar D Bustuoabad; Mónica Vermeulen; Raúl A Ruggiero
Journal:  BMC Cancer       Date:  2022-08-03       Impact factor: 4.638

6.  Optimal Light Dose for hEGFR-Targeted Near-Infrared Photoimmunotherapy.

Authors:  Hideyuki Furumoto; Ryuhei Okada; Takuya Kato; Hiroaki Wakiyama; Fuyuki Inagaki; Hiroshi Fukushima; Shuhei Okuyama; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

7.  Murine Models of Chronic Viral Infections and Associated Cancers.

Authors:  D V Avdoshina; A S Kondrashova; M G Belikova; E O Bayurova
Journal:  Mol Biol       Date:  2022-10-05       Impact factor: 1.540

Review 8.  Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma.

Authors:  Qiang Li; Heng Dong; Guangwen Yang; Yuxian Song; Yongbin Mou; Yanhong Ni
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

Review 9.  Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.

Authors:  Samantha Zottnick; Alessa L Voß; Angelika B Riemer
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

10.  Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects.

Authors:  Ratna Veeramachaneni; Wangjie Yu; Jared M Newton; Jan O Kemnade; Heath D Skinner; Andrew G Sikora; Vlad C Sandulache
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.